A COMPARATIVE STUDY TO EVALUATE THE EFFECTIVENESS OF METFORMIN AND MYOINOSITOL IN THE TREATMENT OF PCOS
Dr. Rekha Garlapati*, Dr. Ashish Agarwal, Dr. R. Nishanth, Dr. Y. Rupa and Dr. T. Lakshmi Teja
ABSTRACT
Introduction: In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. Metformin and Myoinositol being insulin sensitizers improve biochemical, clinical and reproductive parameters in PCOS in women. This study was done to compare the efficacy and safety of Myo inositol versus metformin in PCOS in women. Objective: The primary objective of the study was to study the effect of metformin and myoinositol in the regulation of menstrual cycles. Methodology: A prospective observational study was conducted on 60 patients at DURGABAI DESHMUKH HOSPITAL AND RESEARCH CENTRE, HYDERABAD in department of Gynaecology for a period of six months. Results: There was significant improvement in all the symptoms in both the groups over a period of 6months. However, on comparing both the groups after 6 months, no significant difference was observed in all the symptoms. regulation of menstrual cycles was better with Myo-inositol as compared to Metformin. Conclusion: Our study was to compare the effectiveness of myoinositol versus metformin in PCOS patients. Using clinical assessment, we have shown that myoinositol and metformin, both the drugs resulted in significant weight loss, regularisation of menses. In women with the PCOS, insulin resistance is related to a deficiency in myoinositol containing mediator of insulin action and the administration of the myo-inositol improves insulin sensitivity to conclude, metformin is effective in reducingthe metabolic and hormonal parameters and also improves fertility but myoinositol not only improves all the above parameters but also decreases insulin resistance. Myoinositol also has better patient compliance and well tolerated than metformin.
Keywords: Myoinositol, metformin, polycystic ovarian disease.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
